Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes
ConditionDiabetes Mellitus, Type 2
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorChong Kun Dang Pharmaceutical
About this trial
A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.
Eligibility criteria
Qualifiers
Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment.
Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment.
7.0% ≤ HbA1c < 10.0% based on laboratory tests performed within 4 weeks of enrollment.
Voluntarily give written informed consent after being told about the study.
Disqualifiers
Patients with type 1 diabetes and secondary diabetes.
Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment.
Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study.
End-stage renal disease and hemodialysis patients.
Trial design
Treatments tested in this trial
- SGLT2 inhibitor
- Thiazolidinedione
- DPP-4 inhibitor
Treatment groups
10,000 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov